Inhibikase Therapeutics, Inc. 已披露，公司将通过其“市场发行”（ATM）计划，出售总额达5000万美元的普通股股份。该融资机制允许公司在公开市场交易时段内，根据市场状况灵活地、分期地发行新股，旨在为公司运营及研发活动提供资金支持。
Inhibikase Therapeutics, Inc. 已披露，公司将通过其“市场发行”（ATM）计划，出售总额达5000万美元的普通股股份。该融资机制允许公司在公开市场交易时段内，根据市场状况灵活地、分期地发行新股，旨在为公司运营及研发活动提供资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.